---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-007893"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:54:04.455033+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences reports Q2 preliminary: no revenue, operating loss $1.3M

## Summary
- No revenue for quarter ended June 30, 2025; same as Q2 2024 with zero revenue.
- Expected operating loss of ~$1.3M, improved from ~$2.2M loss in Q2 2024.
- As of June 30, 2025: cash and equivalents $1.8M; total assets $2.6M; working capital $1.2M.
- Firm filed S-1 registration statement to offer shares and warrants in a public offering.

## SEC filing metadata
- accession: 0001654954-25-007893
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495425007893/0001654954-25-007893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495425007893/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-007893
- JSON: https://secwatch.observer/filing/0001654954-25-007893.json
- Plain text: https://secwatch.observer/filing/0001654954-25-007893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.